This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. The FDA's move is bad news for ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

An update to the FDA drug shortage list on Feb. 21 listed the semaglutide shortage as being resolved. In a press release, Novo Nordisk said it is shipping all doses of the medication regularly to ...

Is Compounded Semaglutide Effective for Weight Loss ... Perhaps patients who can’t swallow need a liquid version of a tablet medication, or someone with an allergy needs a dye removed.

On Friday, the FDA reclassified the semaglutide shortage—which had covered multiple doses of Wegovy for obesity and Ozempic for type 2 diabetes—as "resolved" on its online drug shortage database.

Rybelsus tablets come in a child-resistant bottle with a blue cap. The bottle is designed to prevent children from accessing the drug. Be sure to keep the bottle out of reach of children.

Let's take a closer look at each of these medications. Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes. In the intervening years, a lucrative industry of telehealth ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...